Public educational draft · 04 November 2026Clinical review pending →
Oxytocin reference card with source-verified molecular imagery and original research-informed diagrams. Evidence levels and limitations are marked; full citations accompany the card on the website.

Visual summary only. The research findings, limitations and references accompany the card on this page.

The chemical drawing shows source-verified two-dimensional connectivity and stereochemistry, not an experimental three-dimensional conformation. The biological setting is an illustration. Original study diagrams summarize cited research without reproducing publication artwork or inventing quantitative results.

Verified chemical reference record

Read the research ↓ · View all references ↓

Melanocortin / reproductive

Oxytocin

Oxytocin receptor

Oxidized human oxytocin parent; Cys1–Cys6 disulfide; C-terminal glycinamide
Molecular formula
C43H66N12O12S2
Molecular weight
1007.2 g/mol
Class
Cyclic nonapeptide hormone
Identity
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2; disulfide Cys1–Cys6

Research snapshot

Oxytocin is an endogenous hormone involved in uterine contraction and milk ejection. Approved obstetric products have specific clinical uses; a large autism trial found no meaningful social-function benefit.

Established physiology + clinical trials

Identity & representation

Reference parent, not an AXON formulation or salt.

Educational reference only. Not a dosing guide, treatment recommendation or product endorsement.

Nine-residue hormone · Cys1–Cys6 disulfide · C-terminal amide[1]

View the chemical structure →

Sources checked: 2026-11-06. Identity and evidence limits are stated above. Independent specialist review is pending.

ClassCyclic nonapeptide hormone

Research contextOxytocin receptor

EvidenceEstablished physiology + clinical trials

StatusApproved obstetric medicines; other uses differ

What researchers study

Oxytocin is an endogenous hormone involved in uterine contraction and milk ejection. Approved obstetric products have specific clinical uses; a large autism trial found no meaningful social-function benefit.

  • Uterine contractility

  • Milk-ejection physiology

  • Social-behavior clinical research

Mechanism in context

  1. Oxytocin binds its receptor
  2. Cellular calcium signaling changes
  3. Smooth-muscle and myoepithelial contraction follows

Physiological and obstetric effects do not establish benefits for social functioning, mood or general wellness. Medical use requires indication-specific supervision.

Simplified publication-grounded schematic, not a solved protein structure or proof of clinical benefit.

Selected evidence

Established physiology + clinical trials

Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.[3]

Randomized double-blind placebo-controlled phase 2 trial · 290 enrolled; 277 in modified intention-to-treat analysis · 24 weeks

Observed: Primary social-withdrawal score difference was not significant; secondary social/cognitive measures generally did not differ.

Primary social-withdrawal score difference was not significant; secondary social/cognitive measures generally did not differ. Children/adolescents with autism; not evidence of universal social enhancement.

Limit: Children/adolescents with autism; not evidence of universal social enhancement.

Reference identity in detail

Sequences and form distinctions describe the cited reference substance, not a verified supplier preparation.

Read the sequence and form notes
Sequence
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2; disulfide Cys1–Cys6
Residue count
9
Molecular formula
C43H66N12O12S2
Molecular weight (g/mol)
1007.2

Research scope

Targeted source verification, not a systematic review. Citation quality and molecule-specific applicability are stated separately.

Safety & evidence limits

  • Uterine hyperstimulation, rupture and water intoxication are recognized medical risks in product labeling.

  • A 290-participant autism trial found no significant social or cognitive advantage over placebo.

  • Evidence and approvals for pharmaceutical oxytocin do not validate research products or non-obstetric claims.

Practical identity notes

  • Oxidized human oxytocin parent; Cys1–Cys6 disulfide; C-terminal glycinamide
  • No original PubChem 3D conformer was available for this exact reference in the checked endpoint; use exact 2D structure.
  • Reference identity is not confirmation of product contents, purity, sterility or therapeutic equivalence.

The 10-second takeaway

A potent physiological hormone with established obstetric uses; social-enhancement claims do not follow from that evidence.

What the visual panels show

Original diagrams summarize the cited research or documented evidence search. They are not copied publication figures or claims of treatment benefit.

  • MECHANISM / STUDY CONTEXT[2][4]

    Publication-grounded mechanism schematic · Original publication-grounded diagram

    Oxytocin receptor activation · Cellular calcium signaling · Smooth-muscle / myoepithelial contraction

    Interpretation: Physiological and obstetric effects do not establish benefits for social functioning, mood or general wellness. Medical use requires indication-specific supervision.

  • Disulfide ring and tail[1]

    REFERENCE CHEMISTRY · Original publication-grounded diagram

    Nine residues; Cys1–Cys6 bridge

    Sequence topology is not a measured solution conformation.

    Interpretation: Sequence topology is not a measured solution conformation. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.

  • Peripheral hormone functions[2][4]

    ESTABLISHED PHYSIOLOGY · Original publication-grounded diagram

    Uterine contraction and milk ejection

    These functions do not establish social or mood treatment benefits.

    Interpretation: These functions do not establish social or mood treatment benefits. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.

  • Autism social-function study[3]

    HUMAN RANDOMIZED TRIAL · Original publication-grounded diagram

    No significant primary social-withdrawal benefit

    290 enrolled; 24 weeks; pediatric autism population.

    Interpretation: 290 enrolled; 24 weeks; pediatric autism population. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.

Follow the evidence

Sources & what they support

  1. PubChem CID 439302: source reference graph

    Supports: Exact reference graph, stereochemistry, formula and mass

    Original structure record · Download source SDF

    Original PubChem 2D source structure record.

  2. Oxytocin ligand record

    Supports: Receptor pharmacology and identity

  3. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.

    PMID: 34644471 · DOI: 10.1056/NEJMoa2103583

    Supports: 24-week pediatric autism trial

  4. Oxytocin injection prescribing information

    Supports: Obstetric indication; uterine and water-intoxication risks

Source-linked educational drafts. Scientific and clinical review is pending. These cards describe molecules and study context, not product quality, approval or treatment recommendations.

← Explore the Molecular Atlas Continue to the research library →

Advertisement · AXON network

More of AXON.
One place to explore.

These promotional links lead to affiliated AXON websites. Their placement is separate from the educational content and does not validate any product, service or scientific claim.

You will leave this educational preview. Each destination has its own content, access requirements and privacy practices. No advertising tracker or referral parameter is added to these links.